SecProbe.io

January 15, 2020
Mark A. Goldsmith
Chief Executive Officer
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, CA 94063
Re:Revolution Medicines, Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted January 10, 2020
CIK No. 0001628171
Dear Dr. Goldsmith:
            We have reviewed your amended draft registration statement and have the following
comments.  In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments. Unless we note otherwise, our references to prior comments are to comments in our
November 5, 2019 letter.
Amendment No. 2 to Draft Registration Statement on Form S-1
Prospectus Summary
Our product candidates, page 3
1.We note your disclosure on page 4 that you have entered into an agreement with Amgen
to evaluate the combination of RMC-4630 and Amgen's KRASG12C (OFF) inhibitor
AMG 510 in a Phase 1b trial that will be conducted by Amgen.  Please describe the
material terms of this agreement and file it as an exhibit to your registration statement.

 FirstName LastNameMark A. Goldsmith
 Comapany NameRevolution Medicines, Inc.
 January 15, 2020 Page 2
 FirstName LastName
Mark A. Goldsmith
Revolution Medicines, Inc.
January 15, 2020
Page 2
Management’s discussion and analysis of financial condition and results of operations
Comparison of the Results of Operations for the nine months ended September 30, 2018 and
2019, page 95
2.We note your 287%, 95% and 48% increases in collaboration revenue, research and
development expense, and general and administrative expense during the nine months
ended September 30, 2019 compared to the same period in 2018. Please expand each of
these disclosures to explain whether you believe any of these increases represent a trend to
continue in future periods. See Item 303(b) of Regulation S-K, including Instruction 3
thereto.

Management
Compensation committee interlocks and insider participation, page 178
3.Please update to include disclosure regarding the last completed fiscal year.
Exhibits and financial statement schedules, page II-3
4.Please file as exhibits to your registration statement the forms of the new employment
agreements you intend to enter into with your named executive officers in connection with
this offering.
            You may contact Bonnie Baynes at 202-551-4924 or Lisa Vanjoske at 202-551-3614 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Sonia Bednarowski at 202-551-3666 or Dietrich King at 202-551-8071 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences